Hemostemix Logos (400 x 100 px)

TUESDAY, MAY 5, 2026 | 12:00 PM EST | FREE LIVE WEBINAR

When Standard Heart Treatment Isn't Enough: A Stem Cell Research Conversation

 Prof. Dr. Ernst von Schwarz and Dr. York N. Hsiang on investigational cell therapy for angina, heart failure, and ischemic cardiomyopathy 

 Prof. Dr. Ernst von Schwarz is one of the most published cardiologists in the world. He is also one of the few who chose to spend his career studying stem cell therapy for the heart, long before it was accepted, long before it was popular. On May 5 he sits down live with Dr. York N. Hsiang, the Principal Investigator of the Phase II ACP-01 clinical trial. 

 

 
Can't make it live? Register and receive the full replay
  • DAYS
  • HOURS
  • MINUTES
  • SECONDS
 Prof. Dr. Ernst von Schwarz
150+ peer-reviewed publications
Cedars Sinai · UCLA · Heart Stem Inc. 
 
 Dr. York N. Hsiang
 Phase II ACP-01 Principal Investigator
Professor Emeritus, UBC 
 
ACP-01 Phase I Cardiac Studies
50% CCS chest pain reduction at 3 months
Damras, N=24 · Chaithiraphan, N=106 · Schubart, N=54 

YOUR PHYSICIANS

The physicians who never stopped looking.

dr evs

 Prof. Dr. Ernst von Schwarz

MD, PhD, FESC, FACC, FSCAI

 
 

GUEST PHYSICIAN SPEAKER

 A long-standing clinical researcher in stem cell therapy for cardiovascular disease. 30 years. 150+ peer-reviewed publications. Medical Director of Heart Stem Inc. He chose this field before the science caught up. He stayed because the science proved him right. 
1-1

 Dr. York N. Hsiang

MB ChB, MHSc, FRCSC

 

 

MODERATOR - CLINICAL PI

Professor Emeritus of Surgery, UBC. Former Head of Vascular Surgery, Vancouver General Hospital. Principal Investigator of the Phase II ACP-01 clinical trial. He ran the trial. He reviewed the outcomes. He published the results.

 

ONE HOUR

The questions your cardiologist may not have time to answer.

How autologous stem cell therapy works at the biological level and why it is being studied for patients whose blood is not reaching where it needs to go 

What the Phase II investigational data shows across ischemic conditions, and what Prof. Dr. von Schwarz has observed in his own cardiac practice over 30 years 

How patients in Florida are currently accessing ACP-01 through a physician-supervised pathway, and what the intake process looks like from first conversation to treatment
This webinar is for you if:
You or someone you care for has been diagnosed with a heart condition including heart attack, angina, ischemic cardiomyopathy, or heart failure, and you are looking for what else is possible 
You have been through the cardiology system and feel like you are being managed rather than treated 
You want to hear stem cell therapy discussed by physicians who have published the science and treated the patients — not by a clinic or a salesperson
Reserve your seat.

Tuesday, May 5, 2026

12:00 PM EST / 9:00 AM PST
Live on Zoom. 60 minutes. Q&A included.
Can't make it live? Register and we will send you the full replay.

  •  
 ⚖️ Florida SB 1768 — Mandatory Statutory Notice (Required in all advertisements)
THIS NOTICE MUST BE PROVIDED TO YOU UNDER FLORIDA LAW. This physician performs one or more stem cell therapies that have not yet been approved by the United States Food and Drug Administration. You are encouraged to consult with your primary care provider before undergoing any stem cell therapy.
ACP-01 is an investigational autologous angiogenic cell therapy. It is not approved by the FDA or any other regulatory authority. This webinar is for informational purposes only and does not constitute medical advice, a treatment recommendation, or a clinical consultation. Individual patient outcomes may vary. Speak with your physician about your specific medical situation.
 
Hemostemix Inc. (TSXV: HEM | OTCQB: HMTXF | FSE: 2VF0)